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Tetraspanin-enriched microdomainsInjection of tumor cells inmicemore than 30 years ago resulted in the discovery of an epithelial antigen, later de-
ﬁned as a cell adhesion molecule (EpCAM). Although EpCAM has since evoked signiﬁcant interest as a target in
cancer therapy, mechanistic insights on the functions of this glycoprotein have been emerging only very recently.
This may have been caused by the multitude of functions attributed to the glycoprotein, its localization at differ-
ent subcellular sites and complex posttranslationalmodiﬁcations. Here,we reviewhowEpCAMmodiﬁes cell–cell
contact adhesion strength and tissue plasticity, and how it regulates cell proliferation and differentiation. Major
knowledge derived from human diseases will be highlighted: Mutant EpCAM that is absent from the cell surface
leads to fatal intestinal abnormalities (congenital tufting enteropathy). EpCAM-mediated cell proliferation in can-
cer may result from signaling (i) via regulated intramembrane proteolysis and/or (ii) the localization and associ-
ationwith binding partners in specializedmembranemicrodomains. New insight in EpCAM signalingwill help to
develop optimized cancer therapies and open new avenues in the ﬁeld of regenerative medicine.
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In multicellular organisms, epithelium lining all external and in-
ternal surfaces provides a major barrier that prevents unrestricted ex-
change between the organism and the external world. The two main
types of epithelium are (i) simple epithelium and (ii) stratiﬁed epi-
thelium. Simple epithelium consists of a tightly packed and organized
monolayer of polarized cells and can generally be found in organs in
which absorption, secretion, or ﬁltration occurs, such as in the intes-
tine, the exocrine pancreas and the kidney. Stratiﬁed epithelium con-
sists of multiple cell layers, and e.g. can be found in the skin, the
cornea and the oral cavity. Characteristic features for simple epithelia
are microvilli or cilia on the apical domain, high abundance of cell-cell
junctions on the lateral domains, and cell attachment to basal mem-
branes via focal adhesions and hemidesmosomes (Fig. 1). Dysfunction
of epithelia due to cellular or molecular abnormalities can give rise to
a number of diseases, including cancer.
The epithelial barrier function is primarily maintained by tight junc-
tions (TJ; Zonula occludens; Fig. 1), which form an impermeable, or reg-
ulated semi-permeable, seal between the apical and basolateral
domains of the cells. Cell adhesion is a critical regulator of cell polarity
which in turn affects cellular functions as diverse as cell migration, pro-
liferation and differentiation when epithelial cells adhere to neighbor-
ing cells, so-called contact inhibition [1]. Contact inhibition is crucial
in organogenesis and wound healing [2,3]. In cancer, loss of contact in-
hibition may result in uncontrolled cell movement and proliferation,
allowing cells to invade neighboring tissue and to metastasize [4]. Cell
adhesion is mediated by transmembrane cell adhesion molecules
(CAMs), some of which are subdivided into four families: cadherins,
selectins, integrins, and immunoglobulin (Ig)-like CAMs (Fig. 1). Addi-
tionally, there are several CAMs that do not belong to any of these fam-
ilies [5]. In general, CAMs can promote cell–cell adhesion or cell–matrixClaudins, Occludins
Cadherins
desmosomal 
Cadherins
Connexins
Selectins
Ig-superfamily CAMs
Integrins
Extracellular matrix
Fig. 1. Cell adhesion molecules (CAMs) and junctional complexes are abundant in epithelial t
ﬁlaments. (2) Adherens junctions are plaques of classical cadherins linked to the actin cytos
ﬁlaments. (4) Gap junctions connect the cytoplasm of two adjacent cells and are linked to m
the classical families can promote homophilic adhesion outside of junctions. Integrins bind
(linked to intermediate ﬁlaments) are cell–matrix junctions that are formed by integrins.adhesion by homophilic or heterophilic interaction (Fig. 1). One cell ad-
hesion protein that does not ﬁt into any of the “classical” families of ad-
hesion molecules, which was discovered as one of the ﬁrst cancer
markers, is the epithelial cell adhesion molecule (EpCAM; CD326). In
the 1970s, functional screens were performed for novel tumor-speciﬁc
cell surface antigens [6,7], in whichmonoclonal antibodies were gener-
ated by immunization of mice with cancer cells and production of
antibody-secreting hybridomas. Using the newly generated antibodies,
EpCAM was identiﬁed as a tumor antigen [7]. EpCAM is a cell surface
glycoprotein of approximately 40 kDa (detailed below) that is highly
expressed in epithelial cancers and at lower levels in normal simple ep-
ithelia. Due to its simultaneous discovery by many research groups,
EpCAM received a variety of names (Table 1). Several of these names
are still in use, which complicates the linking of studies to the properties
of EpCAM [8]. Since 2007, consensus has been reached to use EpCAM as
the primary name [8].
Due to its frequent overexpression in tumors, EpCAM has been of
signiﬁcant interest for the diagnosis and therapy of various epithelial
cancers, and several EpCAM-directed antibody- or vaccine-based clini-
cal trials for a wide variety of carcinomas have been conducted [8,9].
Apart from being targeted as a molecular biomarker, EpCAM plays a
morphoregulatory role in normal epithelia and stem/progenitor cells,
as well as it may actively drive tumor progression in cancer cells. High
expression of EpCAM is often associatedwith decreased patient survival
[10–15]. Recently, mutations in the EpCAM gene have been discovered
to be responsible for a disease that affects the intestinal epithelium,
leading to intractable diarrhea in infants [16]. While the name EpCAM
originates from studies demonstrating that the protein can promote
homophilic adhesion [17], forced expression of EpCAM has also been
shown to interfere with E-Cadherin-mediated cell adhesion, suggesting
a role as a functional antagonist for classic cadherin-mediated cell–cell
interactions [18]. In addition, EpCAMhas been implicated to be involved(1) Tight junction
(2) Adherens junction
(3) Desmosome
(4) Gap junction
(6) Focal adhesion,
Hemi-desmosome
Epithelial cell
(apical side)
(5) Non-classical junctions
issues. (1) Tight junctions build a seal between adjacent cells and are connected to actin
keleton. (3) Desmosomes are formed by desmosomal cadherins, linked to intermediate
icroﬁlaments. (5) Selectins, Ig-superfamily CAMs, but also other CAMs not belonging to
in a heterophilic manner. (6) Focal adhesions (linked to actin) and hemi-desmosomes
Table 1
EpCAM's various names based on monoclonal antibodies or cDNA clones. *murine
EpCAM.
Abbreviation Name Ref.
(CO)17-1A n.a., mAb from immunization with colon adenocarcinoma cells [7]
TROP-1 Trophoblast cell-surface antigen [21]
MH99 n.a. (mAb) [22]
KS1/4 Carcinoma-associated glycoprotein [23]
323/A3 n.a. (mAb) [24]
HEA125 Human epithelium antigen [25]
EGP34 Epithelial glycoprotein of Mr 34,000 [25]
ESA Epithelial surface antigen [26]
KSA Adenocarcinoma-associated antigen [27]
AUA1 n.a. (mAb) [28]
gp 38 Glycoprotein of 38 kDa [29]
Ber-EP4 n.a. (mAb) [30]
MOC31 n.a. (mAb) [31]
GA733-2 n.a., mAb from immunizationwith gastric adenocarcinoma cells [32]
FU-MK-1 n.a. (mAb) [33]
311-1K1 n.a. (from cDNA clone) [34]
EGP-2 Epithelial glycoprotein-2 [35]
EGP40 Epithelial glycoprotein of Mr 40,000 [36]
Ep-CAM Epithelial cell adhesion molecule [17]
TACSTD-1 Tumor-associated calcium signal inducer 1 [37]
MK-1 n.a. (derived from mAb FU-MK-1) [38]
CD326 Cluster of differentiation 326 [39]
G8.8* n.a. (mAb recognizing murine EpCAM) [40]
1991U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001in a diversity of processes including cell proliferation, migration, adhe-
sion, differentiation, and cell signaling [5,19]. Proliferation induced by
EpCAM-overexpression has been shown to correlate with upregulation
of cell cycle-related proteins [20]. Although several models of EpCAM
signaling have been suggested, the molecular basis of EpCAM-
mediated signaling in healthy tissue, cancer, and in conditions such as
congenital tufting enteropathy is not yet fully understood. In this re-
view, we provide a general overview of the current knowledge on
EpCAM with a focus on functional and structural aspects of this mole-
cule in health and disease.
2. EpCAM: gene, protein, and structure
Human EpCAM is a polypeptide of 314 amino acids (aa), consisting of
a large extracellular domain (N-terminal) of 242 aa, a single-spanning
transmembrane domain of 23 aa and a short cytoplasmic domain of 26
aa (C-terminal) [27] (Figs. 2 and 3). The gene encoding for human
EpCAM is located on chromosome 2 (location 2p21) and has an estimat-
ed size of 14 kb [19,41,42]. Comparison of the genomic and cDNA se-
quences has shown that the EpCAM‐encoding gene (epcam) consists of
9 coding exons: EpCAM's extracellular domain, including the signal pep-
tide, is mainly encoded by exons 1 to 6, the transmembrane region by
exon 7. The intracellular domain is encoded by exons 8 and 9 (last 13
amino acids) [19,42] (Fig. 2). The EpCAMgene is conserved inmany spe-
cies, including, mouse, rat and zebraﬁsh. Moreover, the EpCAM protein
seems to be highly conserved among higher vertebrates, showing upChromosome 2  
Protein
A 
B 
1 59 135
SP TY motif 1  
Exon 1 5
amino acid
position 23 27 66
2 3 4
Fig. 2. Structure of the EpCAM encoding gene (A) and protein (B). The EpCAM encoding gene
as indicated. SP = signal peptide; TY = thyroglobulin-like domain; TM = transmembraneto 81% amino acid sequence homology between man and mouse, and
up to 99% between man and gorilla.
2.1. The extracellular domain of human EpCAM
EpCAM´s extracellular domain starts with the signal peptide, which
is cleaved off predominantly between alanine 23 and glutamine 24
[27,41,43] (Fig. 3). N-terminal sequencing revealed a minor alternative
cleavage of the signal peptide after residue 21 (1%) [43].
Different models of the tertiary structure of EpCAM´s ectodomain
have been developed, deﬁning three motifs. Balzar and colleages
have suggested that EpCAM´s extracellular domain contains a tandem
of epidermal growth factor(EGF)-like repeats (amino acids 27–59 and
66–135), which closely resemble the fourth and ﬁfth EGF-like motif in
the rod domain of nidogen, a basement membrane glycoprotein in-
volved in cell–matrix adhesion [44]. However, determination of the
exact disulphide bond assignments of the protein by Chong and
Speicher has revealed that the ﬁrst motif in EpCAM's ectodomain
shows a novel pattern of disulphide linkage that does not resemble
an EGF-like domain [43]. The second motif does not represent an
EGF-like repeat, but it rather resembles a thyroglobulin (TY) type
1A repeat, as proposed in earlier studies [41–43,45] (Fig. 3). Thyro-
globulin type 1 domains are conserved in a number of proteins and
capable of binding and thereby inhibiting certain cathepsins (cysteine
proteases) which are involved in cancer progression [46,47]. Whether
EpCAM plays a role as a substrate or inhibitor of cathepsins is not
known. Following the TY-repeat, there is a third motif that is cysteine-
free and unrelated to any known molecule.
EpCAM contains three N-glycosylation sites [26,48]. In insect cells,
Asn198 is not glycosylated (Cysteine-poor region), whereas Asn111 is
completely andAsn74partially glycosylated [43] (TY-repeat, Fig. 3). How-
ever, in human and murine cell lines, point mutations of the potential
N-glycosylation sites have shown that all three sites are glycosylated
[49]. Glycosylation of Asn198 seems to be of high importance for
EpCAM´s cell surface expression and protein stability [49]. Mutation of
the Asn198 glycosylation site led to decreased expression of EpCAM. Fur-
thermore, elimination of all three glycosylation sites reduced the half-life
time of the protein from 21 to 7 h when compared to wt EpCAM. Since a
number of cell surface molecules such as Notch, E-Cadherin, integrins,
and CD44 are differentially glycosylated in carcinoma versus normal epi-
thelia [50–53], differential glycosylation of EpCAMmight be an important
factor causing differences in the function of EpCAM in healthy versusma-
lignant tissue. In head and neck carcinoma, EpCAMhas been shown to be
hyperglycosylated in comparison to healthy tissue [54].
2.2. The intracellular domain
Following the transmembrane domain, which is involved in the
association with tight junction protein Claudin7 [55] (Fig. 3; see
Section 3.3), EpCAM´s short cytoplasmic domain consists of 26 aa of
which 14 are charged. Using EpCAM mutants with deletions in the265 314
TM 
8
288
6 7 9
(GA733-2, epcam) consists of 9 exons located on chromosome 2. The protein is encoded
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CK
C
FC
A LN
M 1
A
P
P Q V L A F G
10
L L L A A A T A T F
20
A A A Q E E V C E
30
N Y K L A V N C V
40 N
N
N
R
QCQL K S G N M E A K
70
M V L K A A L K S
60
C I V T N Q A G V S
50
TR
80
G
N
90
QLAGE
P
A
R
N D G L Y D P D C D
100
E S G L F K A K C
110
Q N G T S T
C
W
C
VN
120
TAE T D
130
K D T R R V G
TRLSK
160
SD
Y
A L Q K E I
170
T T R Y Q L D P K F
180
I T IS L Y E N N
P
V
190
I T I D L V Q N S S
200
Q K T Q
N
D
V
DIQT
L
I
Y
250
G P D L D L
240
Q E G N V T L D M K
230
K S FH L S E G K V
220
D K E F Y Y A V D A
210
FEPAKED
V
Y
S
260
M Q
G
L
K
R
290 K K R M A K Y E K A
300E
I
K
E
M
MGEE R
310
H
G
I
A
IA
270
V
A
M
V V V V I V
V
280
A G I
VL
VV
V
1
Cleavage site
Disulphide bond
N-glycosylation site
Putative PDZ-binding site
Association with Claudin-7 (Nuebel et al. 2009)Signal peptide
EpCAM motif 1
Thyroglobulin type 1-repeat (motif 2) α-actinin binding sites (Balzar et al.1998)
S
intracellular
extracellular
TR
140
TYWII V R E S C IKH
150
KARE
K
L E I
Fig. 3. Amino acid sequence of EpCAM. Reproduced and adapted from Schnell et al. [58].
1992 U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001
1993U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001intracellular domain, Balzar and colleagues [56] determined two po-
tential α-actinin binding sites at positions 289 to 296 and 304 to
314 (Fig. 3), which are reportedly important for EpCAM´s localization
at cell-cell contacts and therefore for the cell adhesion properties of
the molecule [56] (see Section 3.1). At the C-terminus, amino acids
Leu312, Asn313 and Ala314 display a putative PDZ binding site
(Fig. 3). In most other cell-cell contact proteins, the hydrophobic
C-terminal aa can interact with multi-PDZ domain proteins that are
key in complex formation with signaling or structural proteins.
Whether this is the case for EpCAM is currently not known.
2.3. EpCAM cleavage
Proteolytic cleavage of EpCAM at multiple sites has been implicated
in its function. Like many other transmembrane proteins, EpCAM con-
tains a signal peptide that is cleaved off by a signal peptidase (see before;
Fig. 3, arrow 1). Furthermore, EpCAM can be cleaved between Arg80 and
Arg81, located in the second motif (TY-repeat) of the ectodomain
[27,42,49] (Fig. 3, arrow 2). The cleaved peptide has a molecular weight
of 6 kDa and remains attached to the32 kDa part via the disulphide bond
between Cys6 and Cys7 (Fig. 4). Notably, the majority of mAbs that rec-
ognize EpCAM on cancer cells bind speciﬁcally to this 6 kDa part,
underlining its high immunogenicity [48,57]. A number of proteases, in-
cluding serine proteases trypsin and chymotrypsin, have been shown to
be able to conduct this N-terminal cleavage of EpCAM [48], which occurs
in a variety of epithelial cancer cell lines originating e.g. from colon, ovar-
ian, and breast cancer [26]. Whether or not and to which extent
N-terminal cleavage occurs depends on the presence and activity of the
relevant proteases [26]. Although EpCAM's limitedN-terminal proteolyt-
ic cleavage was discovered more than three decades ago and suggested
to be of functional importance [48], the effects of this post-translational
modiﬁcation on EpCAM's structure and function are still unknown.
While the two cleavage sites described above are the only truly
identiﬁed, EpCAM might be cleaved by additional proteases which
will be discussed below. A comprehensive overview about the various
proteolytic cleavage events in EpCAM is provided in Schnell et al. [58].
2.4. EpCAM's homologue TROP-2
The only molecule known to be homologous to EpCAM is the
GA733-1 gene product TROP-2 (Trophoblast cell-surface antigen-2),
showing approximately 49% sequence identity and 67% similarity tak-
ing into account conserved substitutions [19,41]. The most prominent
regions of homology are the transmembrane region, and a region inA (1) non-cleaved (2) cleaved,
non-reduced
(3)
r
38 kD 38 kD 32
Fig. 4. N-terminal cleavage of EpCAM. (A) Schematic representation of EpCAM in its non-
cleaved part is no longer connected (3). Red arrow: Arg80/81 cleavage site. (B) Lysates of co
EpCAMmotif 1. [35S]Methionine-labeled immunoprecipitates were analyzed under non-red
from Thampoe et al. [26]; Schnell et al. [58]).the extracellular domain that is homologous to the type 1 repeat of
thyroglobulin. Like EpCAM, TROP-2 contains twelve cysteine residues.
Remarkably, the positions of these cysteines as well as the overall
distribution of hydrophilic and hydrophobic residues are conserved in
both proteins [41]. Instead of three, TROP-2 (36 kDa) contains four
N-glycosylation sites, resulting in a total molecular weight of 50 kDa.
Two of these glycosylation sites are conserved in EpCAM [41]. Whereas
the conserved tyrosine residue present in both proteins has never been
reported to be phosphorylated, TROP-2 has been found phosphorylated
within the cytoplasmic domain at Ser303, which is not conserved in
EpCAM [59,60]. While phoshorylation of TROP-2 by protein kinase C
may be essential for tumor growth promoting signaling of the protein
[60], it does not seem to play a role in EpCAM-mediated signaling.
Like EpCAM, the TROP-2 protein is mainly expressed in epithelial
tissue. However, expression levels do not seem to correlate: TROP-2
can be low in tissues with relatively high EpCAM expression, such
as colon and lung tissue, whereas expression levels can be relatively
high in EpCAM-negative epithelium [19]. Nevertheless, high levels
of TROP-2 expression in a variety of late-stage epithelial carcinomas
(pancreatic, colorectal, gastric and squamous cell-carcinoma of the
oral cavity) are associated with decreased patient survival, as well
as increased tumor aggressiveness and metastasis [60].
3. EpCAM function
3.1. EpCAM and adhesion?
While EpCAM was discovered in a tumor-marker assay, its func-
tion remained elusive. Sequence homology to nidogen, a basement
membrane protein mediating cell-matrix adhesion, suggested that
EpCAM might be involved in cell–matrix or cell–cell adhesion [42].
The name EpCAM -or epithelial cell adhesion molecule—was intro-
duced by Litvinov and colleagues [17], who showed that EpCAM can
mediate Ca2+-independent homophilic cell–cell adhesion in cells
that normally lack cell–cell interactions [17]. Expression of EpCAM
in EpCAM-negative cells led to aggregation of cells and the formation
of cell–cell contacts. In a mix of EpCAM-positive and EpCAM-negative
L-cells, cell aggregates mainly consisted of EpCAM-positive cells
(90%), pointing to homophilic adhesion. Using a range of EpCAM
deletion mutants, Balzar et al. have demonstrated that all the motifs
in EpCAM's extracellular domain are required for the formation of
homophilic intermolecular binding and EpCAM accumulation at
cell-cell adhesion sites [57]. However, also the short intracellular do-
main, which might connect EpCAM with the actin cytoskeleton via1 2
B cleaved,
educed
 + 6 kD
38 kD
32 kD
6 kD
cleaved (1) and cleaved state (2). After reduction of disulﬁde bonds (blue lines), the
lon cancer cell line SW480 were immunoprecipitated with antibody MH99, recognizing
ucing (1) and reducing conditions (2) on 15% acrylamide gels (reproduced and adapted
1994 U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001α-actinin (see Section 2.2), is essential for EpCAM localization at
cell-cell contacts and therefore for EpCAM's ability to mediate adhesion
[56]. While it was concluded that EpCAM itself is an adhesionmolecule,
an alternative explanation of the effects in these expression studies is
that EpCAM modulates classical cell–cell adhesion, which might be at
the protein level, or by regulation of transcription (see below).
While being able tomediate homophilic adhesionwhen introduced in
cells that lack their own means of cell-cell interaction, EpCAM is neither
structurally related to any of the four major families of CAMs [18] nor as-
sociated with any classical junctional structure [61]. In human colon epi-
thelium as well as in epithelial cell lines, EpCAM could not be detected at
tight junctions, desmosomes or cell–matrix adhesions, whereas it partly
co-localized with E-Cadherin at the lateral membrane [61,62].
When compared to E-Cadherin, EpCAM is a relatively weak cell–
cell adhesion molecule [17,18]. Unlike E-Cadherin expressing cells,
which are tightly connected due to adherens junctions, EpCAM ex-
pressing cells are only loosely interconnected [18]. Remarkably,
when co-expressed in E-Cadherin expressing cells, EpCAM weakens
E-cadherin-mediated intercellular adhesion [18]. This weakening
is not due to lower E-Cadherin levels or lack of its cell-surface local-
ization, but results from reduced stability of E-Cadherin-mediated
adhesion due to disturbance of E-Cadherin association with the cy-
toskeleton via α-actinin [18]. Other typical epithelial features, such
as contact inhibition and polarization, are less strong in EpCAM-
expressing cells when compared to E-Cadherin-expressing cells [17].
Conditional knock-out of murine EpCAM in dendritic Langerhans cells,
which also express E-Cadherin, attenuates the migration and motility
of these cells due to increased adhesiveness [63]. These ﬁndings and
the cancer cell invasion and metastasis promoting role of EpCAM in
tumors suggest that EpCAMacts as a negative regulator of adhesion [63].ADAM17
intracellular
extracellular
EpCAM
EpEX
1 2
4
β-catenin
F
Fig. 5. EpCAM as a substrate for regulated intramembrane proteolysis (RIP). Full-length EpC
act as a homophilic ligand for non-cleaved EpCAM, inducing RIP (grey dotted arrow). Follow
by PS-2 (3). EpICD associates with FHL-2 and β-catenin and translocates to the nucleus (4),
Maetzel et al. [74]. See main text for details and abbreviations.Being part of adherens junctions, E-Cadherin is fundamental for the
maintenance of the normal architecture of epithelial tissues [64]. Loss
of E-Cadherin expression can result in loss of cellular polarity and con-
tact inhibition, unregulated growth and invasion of tumor cells in adja-
cent tissues [65–70]. In most epithelia, E-Cadherin and EpCAM are
co-expressed duringdevelopment and in post-natal life. However, an in-
creased or de novo expression of EpCAM is often associatedwith tumoral
transformation which can progress to malignancies andmetaplastic be-
havior [17,18,71], whereas E-Cadherin exhibits tumor-suppressing and
growth-inhibitory functions [72]. By weakening Cadherin-mediated
cell–cell adhesion, EpCAMmight foster higher cell plasticity within epi-
thelial tissues, which in turn may help promote cell proliferation and
motility both during morphogenesis, and during the development and
progression of malignancies. In addition to affecting E-Cadherinmediat-
ed adhesion, EpCAM has recently been shown to be involved in the reg-
ulation of the epithelial integrity by affecting the composition and
function of tight junctions via interaction with claudins [73,62].
In conclusion, although EpCAM is able to promote homophilic cell–cell
interactions, its functional antagonism on E-Cadherin-mediated adhe-
sions suggests that it operates as amodulator of the strength of cell adhe-
sion rather than as a promoter of epithelial cell aggregation and junctional
complex formation [63]. In this regard, compared to Cadherin-mediated
adhesions, EpCAM´s anti-adhesive effect might well be tightly regulated
and coordinated during morphogenesis and tissue regeneration [18] but
disrupted during neoplasm development.
3.2. EpCAM and proliferation
Besides EpCAM's increased/de novo expression in metaplasia and
neoplasia, its abundant expression on fast proliferating tumors points-secretase 
(PS-2)
EpICD
nucleus
Target genes
3
LEF-1
HL-2
AM (1) is cleaved by ADAM17, releasing EpCAM's ectodomain (EpEX) (2). EpEX might
ing the ﬁrst cleavage step, EpCAM´s cytoplasmic tail (EpICD) is released due to cleavage
inducing transcription of EpCAM target genes via LEF-1 consensus sites. Adapted from
1995U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001to a causal relationship and the involvement of EpCAM in growth con-
trol. Several in vitro and in vivo studies have shown that overexpression
of EpCAM, or parts of it (see below), induces cell proliferation, whereas
downregulation of EpCAM decreases cell proliferation [20,74–77]. In-
duction of EpCAM in some in vitromodels results in rapid upregulation
of the oncogenic transcription factor c-Myc, and consequently in
upregulation of cell cycle-related proteins Cyclin A and E, as well as epi-
dermal fatty acid binding protein [20,78]. Using EpCAMmutants, Münz
and colleagues have shown that EpCAM´s intracellular domain is not
only necessary but also sufﬁcient to induce c-Myc upregulation [20].
While EpCAM-mediated induction of Cyclin A and Emight be a second-
ary effect following upregulation of c-Myc, EpCAM has been shown to
have a direct effect on Cyclin D1 at the transcriptional level [77]. A cur-
rent model of EpCAM´s signaling mechanism suggests that EpCAM is
subject to regulated intramembrane proteolysis (RIP; Fig. 5), and that
the cleaved intracellular domain is responsible for the induction of
EpCAM´s target genes [74,77] (see below; Fig. 5).
3.3. Models of EpCAM-mediated signaling
3.3.1. Regulated intramembrane proteolysis
The mechanism of EpCAM-induced proliferation in cancer cells has
been shown to involve regulated intracellular membrane proteolysis
(RIP) [74]. RIP describes an evolutionarily conserved mechanism com-
bining regulated e.g. ligand-induced ectodomain shedding with the
consecutive release of an intracellular domain (ICD) from transmem-
brane proteins [79] (Fig. 5). Both the shed ectodomain and/or the ICD
may activate signaling events. Matrix metalloproteases (MMPs) and
the disintegrin-type metalloproteases (ADAMs, ´A disintegrin and
metalloprotease´) are often involved in protein ectodomain shedding,
whereas, in a second step, γ-secretases including presenilin-1 and 2
(PS-1, PS-2) as active subunits are generating the soluble ICD. Besides
proteins such as Notch and amyloid precursor protein (APP), a num-
ber of CAMs have been shown to undergo proteolytic cleavage, in-
cluding E-Cadherin, CD44 and L1-CAM [1,80–83]. While non-cleaved
E-Cadherin, e.g., acts as a tumor suppressor, different proteolytic frag-
ments of E-Cadherin have been shown to promote tumor progression
[84].
The proteases implicated in RIP of EpCAM are metalloprotease
ADAM17 (also known as TACE: tumor necrosis factor-α-converting en-
zyme) and a γ-secretase containing PS-2 [74]. The initial cleavage re-
sults in the release of a soluble fragment, called EpEX, which may actADAM
-secretase
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EpICD
Cleavage
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Fig. 6. EpCAM signaling in cross-talk with E-Cadherin. EpCAM may weaken E-Cadherin-
mediated adhesion by interrupting the link between E-Cadherin and the actin cytoskeleton.
This might in turn result in increased availability of non-bound β-catenin that may be sta-
bilized by association with EpICD. Adapted from Maetzel et al. [74].as a homophilic ligand for non-cleaved EpCAM. The cleaved intracel-
lular peptide EpICD initiates signaling by association with β-catenin
and four-and-a-half LIM domains protein 2 (FHL2). This complex
may translocate to the nucleus, where it binds LEF-1 and DNA, resem-
bling the canonical Wnt signaling pathway (Fig. 5). LEF-1 is known to
be a major regulator of c-myc and Cyclin E, which represent wnt tar-
get genes and also EpCAM´s target genes [74]. Notably, since EpCAM
itself has been shown to be induced by Wnt signaling [85], EpCAM
cleavage may trigger a positive feedback loop on its expression [74].
Theoretically, EpCAM´s ability to weaken E-Cadherin mediated adhe-
sion (discussed above) might lead to an increase in non-membrane
bound β-catenin [18,86], which may be stabilized and protected
from degradation due to association with EpICD and FHL-2 (Fig. 6).
The fact that expression and regulation of ADAM17 and presenilins,
as well as FHL2, differ between normal versus malignant tissue
might explain EpCAM´s distinct functional properties in health and
disease [74]. Recently, several additional cleavage sites in EpCAM´s
ectodomain have been identiﬁed, suggesting that EpCAM signaling
is regulated via different proteolytic pathways, possibly involved in
controlling EpCAM's multiple functions [58]. Although EpCAM is de-
tectable at low levels in sera of cancer patients [38,87,88], detection
methods used did not distinguish between full-length EpCAM and
its cleaved (partial) ectodomain. However, conclusions should be drawn
with caution since EpCAM is also present on exosomes, microvesicles
abundantly secreted by tumor cells [89].
3.3.2. Tetraspanin-enriched microdomains
Proteolytic processing associated with EpCAM-mediated prolifera-
tion via RIP requires cell-to-cell contacts which represent the initial trig-
ger events [90]. However, not only EpCAM's presence and homophilic
interaction at the cell surface, but also localization in speciﬁc subdomains
of the plasma membrane might be highly important for signaling. A
number of cell signaling events are facilitated by specialized cell-cell con-
tacts [2] (Fig. 1), and by other membrane microdomains such as lipid
rafts, or so-called tetraspanin-enriched microdomains (TEMs), that can
serve as signaling platforms. TEMs are organized macromolecular
complexes formed by tetraspanins, integral transmembrane proteins
that can interact with other tetraspanins, certain lipids, and a variety
of transmembrane and cytosolic proteins [91–93]. Although lipid rafts
and TEMs exhibit some similarities, they can be distinguished by their
distinct protein composition [91]. EpCAM has been identiﬁed as a new
molecule in TEMs, forming a primary complexwith tetraspanin CD9 [94].
Inmetastasizing rat carcinoma cell lines, EpCAMhas been found in a
complex with tetraspanins CD9 and CO-029 (Tetraspanin8), as well as
CD44 variant isoforms (CD44v4-7) (Fig. 7) [95], which are involved in
tumor progression [96]. In contrast to CD9, which has a tumor-/
metastasis-suppressing role, high levels of CO-029 correlate with me-
tastasis and poor prognosis [92,94,97–99]. Another protein in the
EpCAM-CD44v-tetraspanin complex has been identiﬁed as the tight
junction protein Claudin7, which directly binds to EpCAM via an
AxxxG motif within the transmembrane domain [55,100,101] (Fig. 3).
Claudin7 recruits EpCAM into TEMs where it associates with CO-029
and CD44v6 [101] (Fig. 7). The direct association with Claudin7 seems
to be crucial for EpCAM-speciﬁc functions: only in complex with
Claudin7, EpCAM has been found to promote cell proliferation, apopto-
sis resistance, and tumorigenicity [55].
Interestingly, metalloproteases have also been shown to contribute
to the tetraspanin web; ADAM10 for example associates with CD9 and
other tetraspanins [94,102]. ADAM10 and ADAM17, which has been
shown to be involved in EpCAM cleavage [74], are key players in
ectodomain shedding or RIP [103–105]. Tetraspanins might play a role
as regulators of ADAM-induced ectodomain shedding [102,106]: An-
tibodies against tetraspanins, including CD9, speciﬁcally induced
ADAM10- but not ADAM17- dependent cleavage of TNF-α and EGF
in certain cell lines [102]. Another study revealed that CD9 negative-
ly regulates ADAM17 activity [107]. Furthermore, Tetraspanin12 has
TEM
EpCAM Claudin-7 ADAM10
CD9
CD44v6
CO-029
plasma 
membrane
extracellular
intracellular
(1) (2)
(3)
Fig. 7. EpCAM in tetraspanin-enriched microdomains (TEMs). EpCAM associates with Claudin-7 (1) and is recruited to TEMs (2), where it builds a complex with tetraspanins CD9
and CO-029, and CD44v6. ADAM10, also present in TEMs, might be involved in activating EpCAM signaling as presented in Fig. 6 (3).
1996 U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001been shown to promote ADAM10-mediated cleavage of APP and the
maturation of ADAM10 in some cell lines [106]. Among the ADAM
proteases, ADAM17 and ADAM10 are the most closely related [108]
and often share substrates [103–105]. However, while a major fraction
of ADAM10 is localized in TEMs, ADAM17 seems to be sequestered to
lipid rafts [109] and has, except for one study [107], not been found to
associate with tetraspanins [102,106]. The diverse localization of these
twometalloproteases as well as their substrates might be an important
factor in the regulation of ADAM-activity and substrate speciﬁcity. No-
tably, tetraspanins are not only involved in the regulation of ADAM
activity, but were also shown to affect MMPs and to associate with
γ-secretases (reviewed in Yáñez-Mó et al. [110]), implicating that TEMs
might have an important role in the regulation of RIP processes. Since
EpCAM associates with tetraspanins CD9 and CO-029 in TEMs, ADAM10
seems to be a likely candidate for the ectodomain cleavage of EpCAM
(Fig. 7). Further investigation is needed to elucidatewhether tetraspanins
play a role in the regulation of EpCAM signaling.
4. EpCAM in health & disease
4.1. EpCAM in normal tissue and during development
4.1.1. EpCAM expression
In healthy adult tissue, EpCAM is expressed at the basolateral cell
membrane of simple, pseudo-stratiﬁed, and transitional epithelia. No
expression can be detected in the differentiated cells of normal squa-
mous stratiﬁed epithelia. In adults, EpCAM is expressed in most organs
and glands, with the highest expression in colon. Generally, the level
of expression differs between tissues. Typically, in tissues where
EpCAM is present it is high in proliferating cells, and low in differentiat-
ed cells. EpCAM is neither found in cells of lymphoid origin and bone-
marrow-derived cells, nor in mesenchymal, muscular, and neuro-
endocrine tissues [25,111] (see Balzar et al. [19] and Went et al.
[112]). Inmice, the homologue of human EpCAMhas been found in thy-
mic epithelial cells, but also in thymocytes, T-cells and antigen-
presenting dendritic cells [113,114]. In a number of epithelial tissues,
active proliferation corresponds to increased EpCAM levels,whereas dif-
ferentiation is associated with downregulation of the protein (reviewed
in Balzar et al. [19]). In the intestinal epithelium for example, a gradient
of EpCAM can be observed from crypts to villi [19]. This pattern corre-
sponds to high EpCAM levels in the intestinal stem cells, located in the
crypts [115], and decreasing levels when cells are differentiating, at
the top of the villi. Besides in the gut, EpCAM can be found in stem/
progenitor cells of other organs: e.g., hepatocytes are EpCAM-positive
during embryonic liver development, whereas in adults, EpCAM is
only expressed during liver regeneration processes in cells that morpho-
logically resemble precursor stemcells [116]. EpCAM´s higher expression
in fetal epithelia in comparison to adult mature tissues [23] points to a
dynamic regulation of its expression during morphogenesis [117]. Inthe human fetal pancreas, the highest levels of EpCAM can be found in
developing islets budding from pancreatic ducts. In the adult pancreas,
levels are low in differentiated islet clusters but high in duct cells, a com-
partment that has been proposed to comprise progenitor cell popula-
tions for both the exocrine and the endocrine cell lineages [117].
4.1.2. Stem cell marker
EpCAM´s role in the switch between proliferation and differentia-
tion is further sustained by the fact that EpCAM has been identiﬁed as
a surface marker for pluripotent human embryonic stem cells (hESCs)
[118,119] and murine embryonic stem cells (mESCs). In undifferenti-
ated hESCs, EpCAM is co-expressed with pluripotency markers, in-
cluding Octamer 4 (OCT4) and Sex-determining region Y-Box 2
(SOX2) [119,120]. Knock-down of EpCAM results in decreased cell
proliferation and causes signiﬁcant upregulation of endoderm- and
mesoderm-associated genes. However, decreasing EpCAM levels by
silencing did not signiﬁcantly alter the expression of pluripotent
markers. In mESCs, EpCAM expression has been found to be higher
under self-renewal conditions than during differentiation [121]. In-
duction of differentiation caused downregulation of EpCAM along
with decreased expression of c-Myc and pluripotent markers SOX2,
Oct3/4, and Stat3. Downregulation of EpCAM induced similar effects
[121]. Hence, EpCAM is strongly associated with the maintenance of
the undifferentiated state of ESCs upstream of these pluripotency reg-
ulators. The natural mechanism of regulation of EpCAM levels in dif-
ferentiating stem cells might be via epigenetic regulation of the
epcam gene, not by direct methylation, but by activity of histones
[120]. Although this regulation is indirect, modifying EpCAM levels
in mouse ESCs has shown that EpCAM expression may be causally re-
lated to maintaining stem cells [122]: it may initiate the downstream
markers mentioned above, and therefore will be a valuable target for
future avenues to generate human induced pluripotent stem (iPS)
cells.
4.1.3. Knock-down animal models
Due to the lack of genetic loss-of-function studies, the in vivo function
of EpCAM remains poorly understood. Only recently, more and more
EpCAMknock‐out animalmodels are emerging. Loss of EpCAM in the de-
veloping zebraﬁsh led to compromised epithelial plasticity and adhesive-
ness, with hyper-proliferation as a secondary consequence, possibly due
to the loss of contact inhibition [123]. Compromised skin integrity also
resulted in a higher susceptibility for bacterial infections and enhanced in-
ﬂammation [123]. Homozygous deﬁcient EpCAM−/− mice died in utero,
revealing prominent placental abnormalities. EpCAM −/+ mice were
viable and did not show abnormalities [124]. Conditional knock-out of
murine EpCAM in epidermal Langerhans cells, which represent skin-
resident dendritic cells, resulted in a decrease in Langerhans cell motility
and migration, and in compromised regulation of the skin inﬂammatory
response [63]. Recently, a gene-trapped EpCAM knock-out mouse has
1997U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001been obtained that is viable until postnatal day 4 [125], exhibiting the
same histopathological features as seen in patients suffering from CTE
(Section 4.3). Furthermore, two viable EpCAM knock-out mice have
been developed showing intestinal defects [73] in concordance with
what has been found in CTE and has been reported by Guerra et al.
While cell surface EpCAM seems to be crucial for normal development
[126], the molecular mechanism that lead to the intestinal abnormalities,
and whether lower levels of tight junction proteins in mouse models for
CTE are consequence or causative of the malformations in the absence
of EpCAM remains to be identiﬁed.
4.2. EpCAM in cancer
4.2.1. Prognostic marker
EpCAM levels are increased in most epithelium-derived tumors.
High expression levels of EpCAM usually correlate with poor prognosis,
e.g. in breast cancer and ovarian cancer as well as in pancreatic,
urothelial, and gallbladder carcinoma [10–15]. Exceptional cases are
renal and thyroid carcinoma, where high levels of EpCAM have been
shown to correlate with increased survival [127,128]. In several cancer
types EpCAM seems to play a dual role, either promoting or reducing
cancer progression [129]. Overviews of EpCAM regarding tumor prog-
nosis are given in van der Gun et al. [129] and Patriarca et al. [130].
EpCAM's prognostic value has also been assessed in combination with
E-Cadherin and tight junction protein Claudin7, which are both func-
tionally related to EpCAM (Section 3.1). However, co-expression analy-
sis did not improve EpCAM's prognostic value for the presence of nodal
metastases in oral and oropharyngeal squamous cell carcinoma [131].
Since EpCAM might be subject to regulated proteolytic cleavage
(Section 3.3), data regarding EpCAM expression based on immunohis-
tochemistry should be interpreted with caution. Studies using an anti-
body against EpCAM's intracellular domain suggested that nuclear/
cytoplasmic EpCAM staining correlates with the aggressiveness of thy-
roid cancer and overall patient survival, and that this nuclear and
cytoplasmic staining can be speciﬁcally found in epithelial cancers in
contrast to normal tissue [128,132,133]. Althoughwe had similar stain-
ing results in oral and oropharyngeal squamous cell carcinomamaterial,
we could not exclude artifacts due to non-speciﬁc binding of the prima-
ry antibody. Immunostaining artefacts that arise from routine proce-
dures can easily be overlooked if the proper controls are lacking [134].
4.2.2. Cancer therapy
In addition to being of prognostic value, EpCAM is an attractive
target for tumor diagnosis and therapy because of its tumor-
speciﬁc overexpression. EpCAM has been used as a target for many
immunotherapeutic approaches, including treatment with monoclo-
nal antibodies [9] and the development cancer targeting antibodies
[135]. Furthermore, vaccination strategies [136], an EpCAM-speciﬁc
antibody fragment fused to TRAIL (Tumor necrosis factor-related
apoptosis-inducing ligand) [137,138], and toxin-conjugated antibody
fragments [130,139,140] have been developed. Since 2009, the anti-
EpCAM trispeciﬁc antibody catumaxomab (Removab) has been au-
thorized for treatment of malignant ascites in cancer patients; other
EpCAM-directed antibodies and antibody-based constructs are current-
ly in clinical development [8,9].
4.2.3. Lynch syndrome
In addition to its direct involvement in tumor biology (Section 3),
EpCAM plays an indirect role in Lynch syndrome (also known as hered-
itary nonpolyposis colorectal cancer; HNPCC), an autosomal dominant
disorder that predisposes to colorectal adenocarcinoma (60–90%), en-
dometrial carcinoma (20–60%), and various other cancers [141–143].
Tumors observed in Lynch syndrome families are diagnosed at an un-
usual early age and can be multiple. Lynch syndrome is caused by mu-
tations in mismatch repair genes, including MLH1 and MHL2 (mutL
homolog 1 and mutS homolog 2). These mutations prevent the repairof DNA mistakes occurring during cell divisions that may eventually
lead to the development of cancer. Mutations in MLH1 and MSH2 ac-
count for about 80% of Lynch syndrome cases [144].
Recently, heterozygous germline deletions in the EpCAM gene
(epcam), located upstream of MSH2, have been shown to result in
hypermethylation of the MSH2 promoter region and subsequent loss
of MSH2 expression [143]. Deletions of the last exons of epcam lead
to extended transcription into the downstream gene, resulting in an
epcam-MSH2 fusion transcript and methylation induction of the
MSH2 promoter [143]. Nineteen different epcam deletions, all includ-
ing the last two exons, have been identiﬁed in 45 Lynch syndrome
families [141]. Epcam deletions account for approximately 20% of
Lynch syndrome cases showing loss of mismatch protein expression
but lacking the corresponding gene mutations [144]. In total, dele-
tions in epcam inactivate MSH2 in about 1% of individuals with
Lynch syndrome. Due to the tissue-dependent levels of EpCAM ex-
pression, carriers of an epcam deletion have a high risk of colorectal
carcinoma, whereas extra-colonic cancers are rarely found and the
risk for endometrial cancer is reduced [142,145]. In the latter case,
the cancer risk seems to correlate with the size and location of the de-
letion in the EpCAM gene. Thus, genetic screening for EpCAM might
allow optimization of cancer surveillance programs for Lynch syn-
drome families [142].
Histological studies showed a lack of EpCAMexpression in a number
of tumors from patients with epcam germline deletions. In those cases,
EpCAM was only absent in case of homozygous epcam deletion,
resulting from the combination of a germline and a second somatic de-
letion [146,147]. Absence of EpCAM in these tumors seems to be in dis-
agreement with the model of EpCAM being important in tumor
development and progression. This raises the question of whether
EpCAM is overexpressed as a result of tumoral transformation, rather
than playing an active role as a proto-oncogene. In case of Lynch syn-
drome, the absence of mismatch repair proteins might be the dominant
cause for the development of tumors, outrunning possible beneﬁcial ef-
fects due to absence of EpCAM. Notably, only homozygous mutations in
epcam result in loss of EpCAMexpression combinedwithmorphological
abnormalities, as has been shown in knock-out mice (Section 4.1) and
CTE (see below). Thus, while EpCAM is often associated with cancer
progression, it might be secondary to tumor formation in some tumors.
Absence of EpCAMmight therefore not prevent tumor formation.
4.3. Mutations of EpCAM cause congenital tufting enteropathy
Apart from EpCAM´s indirect role in Lynch syndrome, homozygous
mutations in the EpCAM gene have been identiﬁed in patients suffering
from congenital tufting enteropathy (CTE) [16]. CTE is a rare autosomal
recessive formof intractable diarrhea of infancy. Typically, patients devel-
op chronic diarrhea within the ﬁrst days after birth and show impaired
growth. CTE is characterized by subtotal villous atrophywith crypt hyper-
plasia without evidence of inﬂammation. In the typical form, abnor-
malities are localized mainly in the intestinal epithelium and include
disorganization of surface enterocytes with focal crowding, resembling
tufts [148]. Most patients are dependent on parenteral nutrition to
allow normal growth and development. The disease persists through-
out life and imparts signiﬁcant morbidity and mortality [16]. CTE was
ﬁrst described in 1994 [149] with an annual incidence of ~1/100,000
live births in Western Europe. As a result of its severity and rarity, the
pathogenesis of CTE remains poorly understood.
In 2008, the genetic basis of CTE was uncovered: using single nu-
cleotide polymorphism (SNP) genotyping in CTE patient material,
Sivagnanamand colleagues [16,150] identiﬁed several epcammutations,
resulting in a single amino acid exchange, truncation or partial deletion
of the EpCAM protein. Another case study revealed a single basepair in-
sertion, leading to a frame shift and premature truncation of EpCAM
[151]. Further studies revealed novel mutations resulting in premature
stop codons and thereby truncation of the protein [152,153].
1998 U. Schnell et al. / Biochimica et Biophysica Acta 1828 (2013) 1989–2001Generating all EpCAMmutants identiﬁed so far, we recently discov-
ered that all the mutations in EpCAM result in absence of the protein
from the plasmamembrane [126]. This is due to either secretion or deg-
radation of the truncated protein, or to retention of the aberrant protein
in the endoplasmic reticulum. Considering EpCAM´s morphoregulatory
role and its high expression in the intestinal crypts where the stem
cells are located, absence of EpCAMmight disturb normal intestinal de-
velopment. Sivagnanam et al. speculate that EpCAM is involved in the
development of the crypt villus axis, where epithelial cells originate
from stem cells in the crypt and migrate to the tip of the villus [16].
EpCAM´s absence from the cell surface may not only preclude its adhe-
sive function, but might also prevent EpCAM-mediated signaling, in-
volving proteolytic cleavage and association with tetraspanins and
other transmembrane proteins (Section 3.3). Recently, viable EpCAM
knock-out mice have been generated that develop neonatal intestinal
abnormalities [73,125]. In these models, loss of EpCAM has been
shown to affect cell–cell junctions by inﬂuencing the expression and lo-
calization of either adherens junction proteins E-Cadherin and beta-
catenin or tight junction-associated claudins, thereby inﬂuencing the
epithelial integrity and barrier function. Since the knock-outmouse gen-
erated by Guerra and colleagues provides the typical histopathological
features of CTE [125], it represents a promisingmodel for furthermolec-
ular studies and the development of CTE therapies.
Some cases of CTE have been reported as being associated with
chronic arthritis [151] or malformations, including eye-associated ab-
normalities [154]. In a recent study, Roche and colleagues found that
10 out of 15 patients diagnosed with CTE exhibited ophthalmic func-
tional disorders such as superﬁcial punctate keratitis (SPK) and con-
junctival erosive lesions, revealing that CTE might be a multifocal
clinical disease [155]. Beside the characteristic CTE features in the in-
testinal epithelium, also conjunctival tissues showed disorganization
of the surface epithelium with focal crowding, resembling tufts [155].
As a diagnostic feature for CTE, disorganization of surface enterocytes
with tuft-like crowdinghas been considered unique until recently. How-
ever, since the genes for several congenital diarrheal disorders have
been identiﬁed and tufts have been found unreliable as a distinctive fea-
ture for CTE, genetic testing is crucial for a correct diagnosis and optimal
treatment [156].
5. Conclusions, remarks & future perspectives
Although EpCAM has been discovered as a tumor marker more
than three decades ago and is since exploited as a tool for tumor
diagnosis/prognosis and as a target for cancer therapy, it is still not
fully understood how EpCAM is functionally involved in tumor biolo-
gy. Only in recent years, models of EpCAM-mediated signaling on the
molecular level emerged. The discovery of the causal correlation be-
tween EpCAM mutations and CTE highlights the importance of
EpCAM in normal development. From these studies we learned that
EpCAM needs to be present at the cell surface for proper function.
However, the signaling underlying balancing cell proliferation and
differentiation remains pleiotropic. Post-translational modiﬁcation of
EpCAM such as glycosylation and proteolytic cleavage at various sites,
as well as association with binding partners and localization in TEMs
might be crucial for activation and regulation of EpCAM signaling and
dictate the functional outcome.
The differences in EpCAM function in malignant versus healthy
tissues might be explained by differential expression of the various
proteins interacting with EpCAM. Although EpCAM-induced prolifer-
ation is normally triggered by increased, or de novo, expression in
cancer as well as in developing or regenerating tissues, it remains to
be determined if these events are regulated at the level of gene tran-
scription, possibly involving the Wnt pathway [85]. While proteolytic
cleavage of EpCAMmay induce genes via Wnt, EpCAM itself may trig-
ger a positive feedback loop on its expression [74]. Furthermore, abla-
tion or downregulation of tumor suppressor protein p53 is associatedwith an increase in EpCAM expression [157], which might explain
EpCAM´s frequent overexpression in tumors.
EpCAM's signaling mechanism and tissue-speciﬁcity need to be
further clariﬁed to utilize the new knowledge for therapeutic ap-
proaches in cancer and CTE. An important ingredient will be the
three-dimensional structure of EpCAM. Progress toward the resolu-
tion of EpCAM's structural organization [158] may lead to an under-
standing of access to cleavage sites and mechanisms of EpCAM
cleavage, as well as homophilic interactions. In addition, molecular
modeling may aid in the design and evolution of small molecules
to agonize and or antagonize EpCAM's function in patients.
We anticipate that further progress in uncovering EpCAM´s func-
tion in normal developing tissues and in the pathological conditions
such as cancer and CTE will guide the use of this protein as a marker
and/or a target to signiﬁcantly improve the diagnosis, therapy and
prognosis. Ultimately, studies focusing on the function of EpCAM
will also open new avenues of research for tissue engineering and
stem cell treatments.References
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